Skip to main content

Advertisement

Table 2 Hypermethylation frequencies for each gene in each group

From: Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma

Gene Pancreatic cancer (N = 95) Screened negative (N = 27) Chronic pancreatitis (N = 97) Acute pancreatitis (N = 59)
  % n 95% CI % n 95% CI % n 95% CI % n 95% CI
ALX4 17.84 17 (10.78–27.10) 7.41 2 (0.91–24.29) 4.12 4 (1.13–10.22) 1.69 1 (0.04–9.09)
APC 82.11 78 (72.90–89.22) 44.44 12 (25.48–64.67) 54.64 53 (44.21–64.78) 67.80 40 (54.36–79.38)
BMP3 33.68 32 (24.31–44.11) 18.52 5 (6.30–38.08) 3.09 3 (0.64–8.77) 10.17 6 (3.82–20.8)
BNC1 35.79 34 (26.21–46.30) 7.41 2 (0.91–24.29) 5.15 5 (1.69–11.62) 6.78 4 (1.88–16.46)
BRCA1 10.53 10 (5.16–18.51) 14.81 4 (4.19–33.73) 7.22 7 (2.95–14.30) 32.20 19 (20.62–45.64)
CDKN2A 6.32 6 (2.35–13.24) 3.70 1 (0.09–18.97) 2.06 2 (0.25–7.25) 11.86 7 (4.91–22.93)
CDKN2B 12.63 12 (6.70–21.03) 7.41 2 (0.91–24.29) 5.15 5 (1.69–11.62) 11.86 7 (4.91–22.93)
CHFR 1.05 1 (0.03–5.73) 0 0 (0.00–12.77) 3.09 3 (0.64–8.77) 1.69 1 (0.04–9.09)
ESR1 77.89 74 (68.21–85.77) 62.96 17 (42.37–80.60) 60.82 59 (50.39–70.58) 76.27 45 (63.41–86.38)
EYA2 13.68 13 (7.49–22.26) 0 0 (0.00–12.77) 8.25 8 (3.63–15.61) 15.25 9 (7.22–26.99)
GSTP1 3.16 3 (0.66–8.95) 0 0 (0.00–12.77) 1.03 1 (0.03–5.61) 0 0 (0–6.06)
HIC1 15.79 15 (9.12–24.70) 0 0 (0.00–12.77) 6.19 6 (2.30–12.98) 6.78 4 (1.88–16.46)
MESTv2 78.95 75 (69.38–86.64) 44.44 12 (25.48–64.67) 58.76 57 (48.31–68.67) 66.10 39 (52.61–77.92)
MGMT 5.26 5 (1.73–11.86) 0 0 (0.00–12.77) 3.09 3 (0.64–8.77) 0 0 (0–6.06)
MLH1 14.74 14 (8.30–23.49) 22.22 6 (8.62–42.26) 7.22 7 (2.95–14.30) 28.81 17 (17.76–42.07)
NPTX2 74.74 71 (64.78–83.10) 62.96 17 (42.37–80.60) 42.27 41 (32.30–52.72) 49.15 29 (35.89–62.50)
NEUROG1 10.53 10 (5.16–18.51) 11.11 3 (2.35–29.16) 6.19 6 (2.30–12.98) 6.78 4 (1.88–16.46)
RARB 46.32 44 (36.02–56.85) 44.44 12 (25.48–64.67) 28.87 28 (20.11–38.95) 45.76 27 (32.72–59.24)
RASSF1A 42.11 40 (32.04–52.67) 14.81 4 (4.19–33.73) 11.34 11 (5.80–19.39) 16.95 10 (8.44–28.97)
SFRP1 44.21 42 (34.02–54.77) 25.93 7 (11.11–46.28) 17.53 17 (10.55–26.57) 18.64 11 (9.69–30.91)
SFRP2 38.95 37 (29.11–49.50) 18.52 5 (6.30–38.08) 25.77 25 (17.42–35.65) 6.78 4 (1.88–16.46)
SEPT9v2 14.74 14 (8.30–23.49) 0 0 (0.00–12.77) 3.09 3 (0.64–8.77) 1.69 1 (0.04–9.09)
SST 64.21 61 (53.72–73.79) 59.26 16 (38.80–77.61) 30.93 30 (21.93–41.12) 25.42 15 (14.98–38.44)
TFPI2 23.16 22 (15.12–32.94) 3.70 1 (0.09–18.97) 2.06 2 (0.25–7.25) 0 0 (0–6.06)
TAC1 58.95 56 (48.38–68.94) 14.81 4 (4.19–33.73) 35.05 34 (25.64–45.41) 25.42 15 (14.98–38.44)
VIM 3.16 3 (0.66–8.95) 0 0 (0.00–12.77) 0 0 (0–3.73) 0 0 (0–6.06)
WNT5A 8.42 8 (3.71–15.92) 0 0 (0.00–12.77) 1.03 1 (0.03–5.61) 0 0 (0–6.06)
PENK 2.11 2 (0.26–7.40) 0 0 (0.00–12.77) 0 0 (0–3.73) 0 0 (0–6.06)